Related Experiment Video

Updated: Aug 1, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

MKK4 Inhibitors-Recent Development Status and Therapeutic Potential

Leon Katzengruber1, Pascal Sander1, Stefan Laufer1,2,3

  • 1Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmaceutical Sciences, Faculty of Sciences, University of Tuebingen, 72076 Tübingen, Germany.

International Journal of Molecular Sciences
|April 28, 2023
PubMed

Insights

Mitogen-activated protein kinase kinase 4 (MKK4) regulates cell processes and is implicated in aggressive cancers and liver regeneration. Targeting MKK4 offers therapeutic potential for cancer and liver diseases.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Oncology

Background:

  • MKK4 (mitogen-activated protein kinase kinase 4) is a dual-specificity protein kinase regulating JNK and p38 MAPK pathways.
  • MKK4 impacts cell proliferation, differentiation, and apoptosis.
  • Overexpression of MKK4 is linked to aggressive cancers like prostate, ovarian, and triple-negative breast cancer.

Purpose of the Study:

  • To review the significance of MKK4 in cancer development and liver regeneration.
  • To highlight recent advancements in MKK4 drug discovery.
  • To discuss future challenges in developing MKK4-targeting drugs.

Main Methods:

  • Literature review of MKK4's role in disease and regeneration.
  • Analysis of recent findings on MKK4 inhibitors.
  • Discussion of clinical trial progress for MKK4-targeting agents.

Main Results:

  • MKK4 plays a critical role in cancer progression and liver regeneration.
  • MKK4 is a promising therapeutic target for various cancers.
  • MKK4 inhibition is being investigated for liver-associated diseases, potentially as an alternative to transplantation.

Conclusions:

  • MKK4 is a significant molecular target with broad therapeutic implications.
  • The development of MKK4 inhibitors is a rapidly advancing field in drug discovery.
  • Further research is needed to overcome challenges in MKK4-targeted drug development.
Keywords:
MAP2K4MAPKMEK4MKK4cancerclinical trialsdrug designkinase inhibitorsliver failureliver regeneration

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

494
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
219
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K